Validated Hypothesis: CREB-Dependent Differential Complement Regulator Position…

Status: ✅ Validated  |  Composite Score: 0.8332 (83th percentile among SciDEX hypotheses)  |  Confidence: Moderate

SciDEX ID: h-var-92a02b86a1
Disease Area: synaptic biology
Primary Target Gene: CREB1, CD55, CD46
Target Pathway: CREB-mediated complement regulator expression and trafficking
Hypothesis Type: mechanistic
Mechanism Category: proteostasis_stress_response
Validation Date: 2026-04-29
Debates: 1 multi-agent debate(s) completed

Prediction Market Signal

The SciDEX prediction market currently prices this hypothesis at 0.500 (on a 0–1 scale), indicating uncertain, reflecting active debate. This price is derived from community and AI assessments of the probability that this hypothesis will receive experimental validation within 5 years.

Composite Score Breakdown

The composite score of 0.8332 reflects SciDEX’s 10-dimensional evaluation rubric, aggregating independent sub-scores from multi-agent debates:

• Confidence / Evidence Strength: ███████░░░ 0.720

• Novelty / Originality: ███████░░░ 0.750

• Experimental Feasibility: ███████░░░ 0.700

• Clinical / Scientific Impact: ████████░░ 0.800

• Mechanistic Plausibility: ███████░░░ 0.750

• Druggability: ███████░░░ 0.700

• Safety Profile: █████░░░░░ 0.500

• Competitive Landscape: ████████░░ 0.800

• Data Availability: █████░░░░░ 0.550

• Reproducibility / Replicability: ███████░░░ 0.720

Mechanistic Overview

This hypothesis proposes that the CREB-BDNF-TrkB activity-dependent signaling cascade directly controls the spatial positioning and expression levels of complement regulators CD55 and CD46 on synaptic membranes, creating an activity-based tagging system for synaptic elimination. High-frequency neural activity triggers calcium influx and CaMKIV/PKA-mediated CREB1 phosphorylation at serine 133, which transcriptionally upregulates CD55 and CD46 expression while simultaneously promoting their trafficking to active synapses through BDNF-TrkB signaling. The TrkB-activated PI3K/Akt pathway enhances surface insertion of CD55/CD46 at frequently stimulated synapses by phosphorylating trafficking proteins and stabilizing regulator clustering, while the Ras/MAPK cascade reinforces this protective phenotype through sustained CREB activation. Conversely, synapses with low activity levels exhibit reduced CREB-mediated transcription, leading to diminished CD55 and CD46 surface expression and creating microdomains of complement vulnerability. This activity-dependent complement regulator positioning enables precise targeting of weak or silent synapses for complement-mediated pruning while protecting active, functional connections. The differential CD55/CD46 expression creates distinct complement convertase decay rates across synaptic populations—active synapses rapidly dissociate C3 and C5 convertases through high CD55 levels and efficiently cleave complement components via CD46-factor I interactions, while inactive synapses become susceptible to complement deposition and membrane attack complex formation. This mechanism provides a molecular explanation for experience-dependent synaptic refinement during critical periods and may be dysregulated in neurodevelopmental disorders characterized by aberrant pruning.

Evidence Summary

This hypothesis is supported by 9 lines of supporting evidence and 2 lines of opposing or limiting evidence from the SciDEX knowledge graph and debate sessions.

Supporting Evidence

1. CD55 protects synapses from complement-mediated damage (^{1CitationPMID 31611251Open reference}(https://pubmed.ncbi.nlm.nih.gov/31611251/))

2. C3aR1 mediates microglial recruitment to injured neurons (^{2CitationPMID 25361907Open reference}(https://pubmed.ncbi.nlm.nih.gov/25361907/))

3. Dendritic spine CD46 expression is activity-dependent (^{3CitationPMID 28902832Open reference}(https://pubmed.ncbi.nlm.nih.gov/28902832/))

4. Beyond the Role of CD55 as a Complement Component. (2018; Immune Netw; ^{4Citation2018 · PMID 29503741Open reference}(https://pubmed.ncbi.nlm.nih.gov/29503741/); confidence: medium)

5. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. (2022; Nat Cancer; ^{5Citation2022 · PMID 36271172Open reference}(https://pubmed.ncbi.nlm.nih.gov/36271172/); confidence: medium)

6. Nitric oxide induces segregation of decay accelerating factor (DAF or CD55) from the membrane lipid-rafts and its internalization in human endometrial cells. (2012; Cell Biol Int; ^{6Citation2012 · PMID 22574734Open reference}(https://pubmed.ncbi.nlm.nih.gov/22574734/); confidence: medium)

7. Role of transcription factor Sp1 and RNA binding protein HuR in the downregulation of Dr+ Escherichia coli receptor protein decay accelerating factor (DAF or CD55) by nitric oxide. (2013; FEBS J; ^{7Citation2013 · PMID 23176121Open reference}(https://pubmed.ncbi.nlm.nih.gov/23176121/); confidence: medium)

8. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. (2024; Mol Cancer; ^{8Citation2024 · PMID 38853277Open reference}(https://pubmed.ncbi.nlm.nih.gov/38853277/); confidence: medium)

9. CD46 cofactor activity at active synapses enhances factor I-mediated cleavage of C3b and C4b, blocking complement amplification on synaptic membranes (^{9CitationPMID 37515111Open reference}(https://pubmed.ncbi.nlm.nih.gov/37515111/))

Opposing Evidence / Limitations

1. C1q binding can occur independent of complement cascade initiation through pattern recognition (^{10CitationPMID 29257131Open reference}(https://pubmed.ncbi.nlm.nih.gov/29257131/))

2. Global complement enhancement could impair necessary synaptic remodeling (^{2CitationPMID 25361907Open reference}0(https://pubmed.ncbi.nlm.nih.gov/24962259/))

Testable Predictions

SciDEX has registered 4 testable prediction(s) for this hypothesis. Key prediction categories include:

1. Biomarker prediction: Modulation of CREB1, CD55, CD46 expression/activity should produce measurable changes in synaptic biology-relevant biomarkers (e.g. CSF tau, NfL, inflammatory cytokines) within weeks of intervention.

2. Cellular rescue: Neurons or glia exposed to synaptic biology conditions should show partial rescue of survival, morphology, or function when CREB-mediated complement regulator expression and trafficking is corrected.

3. Circuit-level effect: System-level functional measures (e.g. EEG oscillations, glymphatic flux, synaptic transmission) should normalize following successful intervention.

4. Translational signal: Preclinical models should show ≥30% improvement on primary endpoint before Phase 1 clinical translation is considered appropriate.

Proposed Experimental Design

Disease model: Appropriate transgenic or induced synaptic biology model (e.g., mouse, iPSC-derived neurons, organoid)
Intervention: Targeted modulation of CREB1, CD55, CD46 via CREB-mediated complement regulator expression and trafficking
Primary readout: synaptic biology-relevant functional, biochemical, or imaging endpoints
Expected outcome if hypothesis true: Partial rescue of synaptic biology phenotypes; biomarker normalization
Falsification criterion: Absence of rescue after confirmed target engagement; or off-pathway mechanism explaining results

Therapeutic Implications

This hypothesis has a moderate druggability score (0.700). Therapeutic approaches targeting CREB1, CD55, CD46 are feasible but may require novel delivery strategies or combination approaches.

Safety considerations: The safety profile score of 0.500 reflects estimated risk for on- and off-target effects. Any clinical translation should include careful biomarker monitoring and dose-escalation protocols.

Open Questions and Research Gaps

Despite reaching validated status (composite score 0.8332), several key questions remain open for this hypothesis:

1. What is the optimal therapeutic window for intervening in the CREB1, CD55, CD46 pathway in synaptic biology?

2. Are there patient subpopulations (genetic, biomarker-defined) who respond differentially?

3. How does the CREB1, CD55, CD46 mechanism interact with co-pathologies (e.g., tau, amyloid, TDP-43, α-synuclein)?

4. What delivery route and modality achieves maximal target engagement with minimal off-target effects?

5. Are human genetic data (GWAS, rare variant studies) consistent with this mechanistic model?

Related Validated Hypotheses

The following validated SciDEX hypotheses share mechanistic themes or disease context:

• Activity-Dependent CD55/CD46 Trafficking and Synaptic Surface Localization — score 0.833

• Differential Complement Regulator Expression on Synaptic Membranes (CD55/CD46) — score 0.833

• TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Restorative — score 0.813

About SciDEX Hypothesis Validation

SciDEX hypotheses reach validated status through a multi-stage evaluation pipeline:

1. Generation: AI agents propose mechanistic hypotheses from literature gaps and knowledge graph analysis

2. Debate: Theorist, Skeptic, Expert, and Synthesizer agents debate each hypothesis across 10 evaluation dimensions

3. Scoring: Each dimension is scored independently; the composite score is a weighted aggregate

4. Validation: Hypotheses scoring above the validation threshold with sufficient evidence quality are promoted to ‘validated’ status

5. Publication: Validated hypotheses receive structured wiki pages, enabling researcher access and citation

This page was generated on 2026-04-29 as part of the Atlas layer wiki publication campaign for validated neurodegeneration hypotheses.

External Resources

• [NCBI Gene: CREB1, CD55, CD46](https://www.ncbi.nlm.nih.gov/gene/?term=CREB1, CD55, CD46)

• [UniProt: CREB1, CD55, CD46](https://www.uniprot.org/uniprotkb?query=CREB1, CD55, CD46)

• [PubMed: CREB1, CD55, CD46 + synaptic biology](https://pubmed.ncbi.nlm.nih.gov/?term=CREB1, CD55, CD46+synaptic+biology)

• OpenTargets: synaptic biology Targets

• ClinicalTrials.gov: synaptic biology